Clinical trials: Single Dose
Obesity
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Trial name
- NCT07337174
- Testing
- HUC2-676, HUC2-676-R
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
HIV Infections
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
- Trial name
- NCT06741397
- Testing
- CAB LA, New formulation of CAB LA
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Respiratory Depression
ENA-001 for Opioid Induced Respiratory Depression
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.
- Trial name
- NCT06967259
- Testing
- ENA-001
- Where
- 2 sites in United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Enalare Therapeutics Inc.
Pain, Fever
Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients
We are doing this study to find out what happens to acetaminophen in the body after it is given to children through the vein. Children's bodies may handle drugs differently than adults.
- Trial name
- NCT00493246
- Testing
- IV Acetaminophen
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Mallinckrodt
Healthy
Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects
To assess the safety and tolerance of 5 mL to 20 mL PEG 400 in multiple rising doses
- Trial name
- NCT02260076
- Testing
- PEG 400
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
C-Reactive Protein
A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)
The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation…
- Trial name
- NCT07867340
- Testing
- LY5625573, Midazolam
- Where
- 3 sites in United States, Singapore
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alpha 1-Antitrypsin Deficiency
Study of DCR-A1AT in Healthy Adult Volunteers
This is a research study to test an experimental study drug (belcesiran, also known as DCR-A1AT). This drug is being tested to see if it helps people with a rare condition known as Alpha-1 Antitrypsin Deficiency, or A1ATD.
- Trial name
- NCT04174118
- Testing
- belcesiran
- Where
- 2 sites in New Zealand, Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Bioequivalence
Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions
This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Prestarium ® A 10 mg tablets) or the test (Perindopril 8 mg tablets)…
- Trial name
- NCT06213610
- Testing
- Perindopril tablet, Prestarium® A tablet
- Where
- Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pharmtechnology LLC
Healthy
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers
The primary objective of this trial is to investigate the safety and tolerability of BI 655130 in healthy male subjects following IV administration of multiple rising doses.
- Trial name
- NCT02852824
- Testing
- BI 655130 (spesolimab)
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904
The purpose of this study is to assess the safety and tolerability of ION904.
- Trial name
- NCT04731623
- Testing
- ION904
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Healthy
Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers
The aim of the study is to investigate the pharmacodynamics, pharmacokinetics, safety, and immunogenicity of BCD-180 after a single intravenous administration in escalating doses to healthy volunteers.
- Trial name
- NCT05407779
- Testing
- BCD-180, dose 1, BCD-180, dose 2, BCD-180, dose 3
- Where
- Russia
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Biocad
Healthy
A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects
This is a FIH, randomized, double- blind, placebo-controlled, dose -escalation study to investigate the safety, tolerability, PK, and PD of ENN0403 after single and multiple oral dose administration in healthy adult subjects.
- Trial name
- NCT05506540
- Testing
- ENN0403 1mg, ENN0403 4mg, ENN0403 10mg
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- EnnovaBio
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose and pharmacokinetics of MLN0128 in patients with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia
- Trial name
- NCT01118689
- Testing
- MLN0128
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cachexia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses
This study is the first administration of GSK2881078 to humans. The intention of this study is to provide sufficient confidence in the safety of the molecule to inform progression to further repeat dose and proof of concept…
- Trial name
- NCT02045940
- Testing
- GSK2881078
- Where
- 2 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see: how the body processes the study medicine and if food affects the amount of study…
- Trial name
- NCT06686797
- Testing
- PF-08049820
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy
The purpose of this study is to evaluate the efficacy of the Asthma improvement of Flutiform K-haler after 12 weeks of treatment in patients with moderate to severe uncontrolled* asthma following mid-dose ICS/LABA DPI therapy.
- Trial name
- SWIFT (NCT04124510)
- Testing
- Brand Name: Flutiform K-haler
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Mundipharma Korea Ltd
Advanced Solid Tumors
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
This is a non-randomised study in patients with advanced solid malignancies
- Trial name
- ADME (NCT05008913)
- Testing
- [14C]Adavosertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Psoriasis
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
The purpose of this study is to evaluate the potential effects of a single dose of 200 milligram (mg) guselkumab on the plasma concentrations of a cocktail of representative probe substrates of Cytochrome P450 isozymes (CYP3A4…
- Trial name
- NCT02397382
- Testing
- Guselkumab, Midazolam, Warfarin
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Janssen Research & Development, LLC
Cystic Fibrosis
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
- Trial name
- NCT06237335
- Testing
- RCT2100, Ivacaftor
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ReCode Therapeutics
Idiopathic Pulmonary Fibrosis
Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
GSK3008348 is being developed as a treatment for IPF. A first-time-in-human study showed that single nebulized doses of 1-3000 micrograms (mcg) GSK3008348 in healthy volunteers were well tolerated, with pharmacokinetic (PK)…
- Trial name
- NCT03069989
- Testing
- GSK3008348, [18F]-FBA-A20FMDV2
- Where
- 3 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.